Yoga as a non‐pharmacologic therapy to reduce dinutuximab‐induced pain in patients with neuroblastoma

Abstract

AbstractBackgroundAnti‐GD2 antibodies are key components of treatment for high‐risk neuroblastoma; however, they cause neuropathic pain. Yoga therapy may help reduce pain and distress associated with anti‐GD2 therapy.ProcedureChildren 3 years of age or older with neuroblastoma participated in individualized yoga therapy while receiving the anti‐GD2 antibody dinutuximab (DIN). Yoga therapy was deemed feasible if patients participated during 60% or more of DIN admissions. Patients and caregivers assessed pain/distress before and after yoga therapy with a distress thermometer (DT) and Wong‐Baker FACES pain rating scale and completed questionnaires regarding satisfaction with yoga therapy. Therapy was deemed efficacious if there was a ≥1 point pain score change and reduction in distress after yoga.ResultsEighteen patients were enrolled; 52 encounters (admissions for DIN) were evaluable. Ten of 18 were female, three of 18 were Hispanic, and 10/18 were White. Median age at enrollment was 5.5 years (range: 3–11). Yoga therapy was feasible in 39/52 (75%) encounters. Significant reductions in caregiver‐reported pain and distress and reductions in patient‐reported pain and distress after yoga therapy were reported. Twelve of 18 caregivers completed questionnaires: seven agreed/strongly agreed that yoga was valuable, and nine agreed/strongly agreed to continued participation in yoga. Thirty‐four of 36 clinicians reported that they would recommend yoga therapy for other patients receiving DIN.ConclusionsYoga therapy was feasible during DIN therapy and may be effective in reducing DIN‐associated pain and distress. Future studies are needed to evaluate changes in opioid usage with the addition of yoga therapy during anti‐GD2 antibody therapy.